Protalix reports Q3 2026 results, reaffirms revenue guidance, RELEASE gout study enrollingNov 10Quarterly updateProtalix BioTherapeutics, Inc.
Arvinas reports Q3 2026 results, dosing starts in new HPK1 trialNov 3Quarterly updateARV-6723Arvinas Inc.
Merck registers new MK-8644 psoriasis trial; RA and HIV/HPV vaccine trials continueOct 30Weekly roundup, 11 itemscabazitaxeldexamethasoneUpdated
Pfizer wins two FDA labeling supplements; obesity trial roster unchangedOct 15Weekly roundup, 8 itemsberobenatidemethotrexate
Boehringer Ingelheim posts Brightline-2 brigimadlin results; BI 4060107 trial recruitsOct 15Weekly roundup, 5 itemsBoehringer Ingelheimempagliflozin
Pyxis Oncology reports updated Phase 1 data for MICVO in head and neck cancerSep 9Clinical readoutPyxis Oncology, Inc